The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Incretin-based Therapies in the Management of Obesity and its Comorb…

Michigan Medicine

A. Rothberg

Urology - Do This, Don't Do That

OHSU

I. Metzler

Functional Hypothalamic Amenorrhea: Consequences Beyond the Menstrua…

Heart in Diabetes (HiD)

C. Shufelt

Ozempic, Zepbound, and More: Behavioral Interventions & Weight Loss …

Baystate Health

M. Gortakowski, K. Jobbins

Weight Loss and Pharmacologic Management of Obesity in 2024

Caroline Apovian

Pharmacologic Options for Managing Obesity in Patients with Heart Fa…

UCLA Health

V. Surampudi

Improve Your Approach to Preventive Care and Common Endocrine Disord…

Jeanne Novas

Diabetes Updates

Duke Health

T. Setji

Weight Wellness for the PCP: The Next Generation of Anti-Obesity Med…

University of Texas Southwestern Medical Center

J. Almandoz

What's New in the Medical Management of Diabetes? A 2024 Guidelines …

Keck School of Medicine of USC

A. Lampe Dominguez

The Contemporary Management of Heart Failure

Heart in Diabetes (HiD)

A. S. Desai

Practical Pearls for Initiating GLP-1 Therapy for Weightloss

William Mania

GLP1-RA and Risk of Stroke

Heart in Diabetes (HiD)

L. A. Leiter

Intermittent Energy Restriction for Obesity Treatment

University of Colorado Department of Medicine

V. Catenacci

The Dynamic Duo: GLP-1 Receptor Agonists and SGLT2 Inhibitors

Heart in Diabetes (HiD)

R. S. Busch

The Proper Management of a Patient With Heart Failure Circa 2024

Heart in Diabetes (HiD)

S. Greene

STEP-HFpEF DM – What Is the Role of Semaglutide for Patients with Di…

Canadian Collaborative Research Network

N. Singh

Renal Health & Diabetes

Scripps Health

C. Rhee